- MediciNova (NASDAQ:MNOV) is up 10% premarket on light volume. On Friday after the close, it announced positive results from a Phase 2b clinical trial assessing lead candidate ibudilast (MN-166) in progressive multiple sclerosis.
- Previously: MediNova's MN-166 reduced progression of MS by 26% in mid-stage study (Feb. 2)
MediciNova up 10% premarket on positive MN-166 data
Recommended For You
About MNOV Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MNOV | - | - |
MediciNova, Inc. |